Supplementary Figure S1. Model validation and GcgR agonism in GcgR and Fgf21 mice. mRNA expression of *Gcgr*, *Fgf21*, and *Fxr* in GcgR Δ Liver, Fgf21 Δ Liver, Fxr Δ Liver, and littermate Control mice (a, b, and d, n=6-10 mice/group, see Figures 2-4). Plasma FGF21 in 8-week-old, chow fed Fgf21 Δ Liver and littermate Control (WT) mice following 5d Vehicle or IUB288 treatment (c, 10 nmol/kg IUB288, n=4-10 mice/group). *Fxr* mRNA expression in primary hepatocytes isolated from 8-10 week old, chow fed Fxr Δ Liver or littermate control (WT) mice (e). Body weight of DIO WT and GcgR Δ Liver mice (f, n=8-12 mice/group) or WT and Fgf21 Δ Liver mice (g, n=5-7 mice/group) following daily GcgR agonism (10 nmol/kg IUB288). Plasma bile acid levels in IUB288-treated DIO WT and GcgR Δ Liver mice after 2 h fast (h, n=8-12 mice/group, see Figure 2). All data are represented as mean +/- SEM.



Supplementary Figure S2: GcgR agonism and energy balance in FXR-/- mice. Hepatic Fgf21 mRNA expression (a) and plasma levels (b) in HF-fed WT and FXR-/- mice. Body weight (%) and fat mass of HF-fed WT (c and e) or FXR-/- mice (d and f) following daily GcgR agonism (10 nmol/kg IUB288). Change in lean mass (g) and total food intake (h) in HF-fed WT or FXR-/- mice. All data are represented as mean +/- SEM (n=3-8 mice/group). **p< 0.01. Male, WT and Fxr-/- mice were placed on HFD at 8-10 weeks old concurrent with IUB288 treatment.



Supplementary Figure S3. DIO and GcgR agonism in FXRALiver mice. Body composition before (a) and after (b) HF-feeding in WT and FXRALiver mice (n=13-15 mice/group). Average food intake (c) during HF-fat feeding in WT and FXRALiver mice (n=13-15 mice/group). Body weight (d) during daily GcgR agonism (10 nmol/kg IUB288) in WT and FXRALiver mice (n=8-10 mice/group). Intestine and liver *Gpbar1/Tgr5* mRNA expression (e) in 14d IUB288-treated DIO WT and FxrALiver mice. Plasma bile acid profile (f) in male FxrALiver mice following 16d GcgR agonism. *p< 0.05, **p< 0.01. Male, WT and FxrALiver mice were placed on HFD at 8-10 weeks old and maintained on HFD for 10 weeks to induce DIO prior to treatment.



Supplementary Figure S4. Liver and Adipose Tissue morphology following GcgR agonism in FXR Δ Liver mice. Representative haemotoxylin and eosin (H & E) staining of liver, inguinal white adipose tissue, ependymal white adipose tissue, and interscapular brown adipose tissue following 14d IUB288 treatment. Male, WT and Fxr Δ Liver mice were placed on HFD at 8-10 weeks old and maintained on HFD for 10 weeks to induce DIO prior to treatment. Scale bars are 20 µm in length.



Supplementary Figure S5. 7 d indirect calorimetry during GcgR agonism in Fxr Δ Liver mice. Energy expenditure (EE, a-b), respiratory quotient (RQ, c-d), food intake (e-f), and locomotor activity (g-h) measured during 7 d indirect calorimetry analysis (in DIO WT (a,c,e, and g) and Fxr Δ Liver mice (b,d,f, and h) during daily GcgR agonism (10 nmol/kg IUB288). IUB288 administered via subcutaneous injection 1hr prior to dark phase (ZT11). All data are represented as mean +/- SEM (n=6 mice/group, see Figure 5).



Supplementary Figure S6. Transcriptional Analysis of IUB288 Treatment in Fxr Δ Liver and WT Mice. (a) Venn diagram illustrating the selection of FXR-dependent DEGs (shaded). (b) Hierarchical clustering of IUB288 vs. Vehicle comparison (p < 0.05). (c) [14C] Palmitate oxidation in primary hepatocytes isolated from DIO WT and Fxr Δ Liver mice and treated with glucagon for O.N. treatment followed by 3 hr incubation with radioactive substrate.



Supplementay Table 1. qPCR primers

Gene	Forward (5'-3')	Reverse (5'-3')
Gcgr	GCCAGCGAGGTCTCCATA	ACATCATTCACCTTCTTGTGG
Fgf21	CTG CTG GGG GTC TAC CAA G	CTG CGC CTA CCA CTG TTC C
Scl10a1	GCCACACTATGTACCCTACGTCCTC	GAATGTAGCCCATCAGGAAGCCAGTG
Cyp27a1	GAAGGACCACCGAGACCACAAGG	CGT TTA AGG CAT CCG TGT AGA
		GCG
Hmgcr	GTGTTCAAGGAGCATGCAAAG	AGCCATCACAGTGCCACATAC
Cyp7a1	GGGATTGCTGTGGTAGTGAGC	GGTATGGAATCAACCCGTTGTC
Fxr	CACAGCGATCGTCATCCTCTCT	TCTCAGGCTGGTACATCTTGCA
Gpbar1/Tgr5	AAGAGCCAAGAGGGACAATC	GTAGCTGCTGCTTCCCTAAT
Ppargc1a	CCCTGCCATTGTTAAGACC	TGCTGCTGTTCCTGTTTTC
Ppara	AGCAGTGCTGGCTACCTTCAA	AATATGTAGCCACCCCTTGG
Scd1	TCAGAAACACATGCTGATCCTCAT	TGGGTGTTTGCGCACAAG
Srebp1c	GAGGACCTTTGTCATTGGCTG	TACAGAGCAAGAGGGTGCCAT
Hprt	AAGGAGATGGGAGGCCAT	GTTGAGAGATCATCTCCACCAAT
Rps18	TTCTGGCCAACGGTCTAGACAAC	CCAGTGGTCTTGGTGTGCTGA
Ppia	CAGACGCCACTGTCGCTT T	TGTCTTTGGAACTTTGTCTG